WCM
MRTX

Weld Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Weld Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-17,095
Closed -$725K – 930
2018
Q4 		$725K Buy
+17,095
New +$681K 0.16% 223

Other funds holding MRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Weld Capital Management's MRTX Position: Q1 2019 in Review

Weld Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2019, closing a stake of 17,095 shares — an estimated $725K sold.

Weld Capital Management first reported a position in MRTX in Q4 2018 and held it in 1 quarter. The position peaked at $725K in Q4 2018. 159 funds tracked by Wall St. Rank hold MRTX as of Q1 2019.

  • Weld Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Weld Capital Management sold 17,095 Mirati Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $725K.
  • Weld Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Weld Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $725K in Q4 2018.
  • 159 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Weld Capital Management's 13F filing for Q1 2019, filed 15 May 2019.